Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19368009 | 0.83 | ALDH1A1 (0.31) | CYP1A2CYP2C9ALDH1A1MEN1KMT2A | |
| SCHEMBL8370925 | 0.82 | MEN1 (0.31) | CYP1A2CYP2C9ALDH1A1MEN1KMT2A | |
| SCHEMBL21821300 | 0.81 | TSHR (0.42) | CYP1A2ALDH1A1KMT2ACTDSP1SMN1; SMN2 | |
| Bromide SCHEMBL17338086 | 0.80 | SMN1; SMN2 (0.43) | CYP1A2ALDH1A1KMT2ACTDSP1SMN1; SMN2 | |
| SCHEMBL13865792 | 0.78 | GPR84 (0.38) | ALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL575287 | 0.77 | CHRNA7 (0.37) | CTDSP1 | |
| Iodide SCHEMBL9011443 | 0.74 | CTDSP1 (0.36) | CTDSP1 | |
| Bromide SCHEMBL19439575 | 0.74 | CHRNA7 (0.35) | CTDSP1SMN1; SMN2 | |
| SCHEMBL439766 | 0.74 | PABPC1 (0.46) | CYP1A2CYP2C9ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL7057188 | 0.73 | KMT2A (0.34) | CYP1A2CYP2C9ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911399-B2 | Treating and preventing disease with TMA and TMAO lowering agents | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-02-27 | — | — | US | disclosed |
| US-11771659-B2 | Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway | THE CLEVELAND CLINIC FOUNDATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-20170266208-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2017-09-21 | — | — | US | disclosed |
| US-9694020-B2 | Treating and preventing disease with TMA and TMAO lowering agents | THE CLEVELAND CLINIC FOUNDATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160089387-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2016-03-31 | — | — | US | disclosed |
| US-8921515-B2 | Methods and compositions of preparation for proteome analysis | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130172539-A1 | METHODS AND COMPOSITIONS OF PREPARATION FOR PROTEOME ANALYSIS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-07-04 | — | — | US | disclosed |
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-02-05 | — | — | US | disclosed |
| EP-0816381-B1 | POLYETHYLENE GLYCOL MODIFIED HEPATOCYTE GROWTH FACTOR (HGF) | NAKAMURA TOSHIKAZU (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-6380356-B1 | DIMERS WITH GIVEN LINKING GROUPS; USE AGAINST GRAM-NEGATIVE BACTERIAL INFECTIONS | ADVANCED MEDICINE, INC. | 2002-04-30 | — | — | US | disclosed |
| EP-0473084-B1 | Polyethylene glycol derivatives, their modified peptides, methods for producing them and use of the modified peptides | SUMITOMO PHARMA (JP) | 1995-11-15 | — | — | EP | disclosed |
| EP-0333587-B1 | METHOD FOR PURIFYING AND ISOLATING CARBOXYL-TERMINAL PEPTIDES | MITSUBISHI KASEI CORPORATION (JP) | 1993-06-09 | — | — | EP | disclosed |
| US-5214131-A | Polyethylene glycol derivatives, modified peptides and production thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1993-05-25 | — | — | US | disclosed |
| US-5183660-A | Drugs having decreased antigenicity, delayed biological clearance and exhibit physiological activity over a long period | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1993-02-02 | — | — | US | disclosed |
| US-5104973-A | Cleaving peptide bond between lysine residue and adjacent amino acid residue, reacting peptide mixture with solid carrier | MITSUBISHI KASEI CORPORATION (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0473084-A2 | Polyethylene glycol derivatives, their modified peptides, methods for producing them and use of the modified peptides | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-03-04 | — | — | EP | disclosed |
| US-5093531-A | POLYETHYLENE GLYCOL SUBSTITUTED PHENYL GLYOXALS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-03-03 | — | — | US | disclosed |
| EP-0400486-A2 | Polyethylene glycol derivatives, modified peptides and production thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-12-05 | — | — | EP | disclosed |
| EP-0340741-A2 | Polyethylene glycol derivatives, modified peptides and production thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1989-11-08 | — | — | EP | disclosed |
| EP-0333587-A2 | Method for purifying and isolating carboxyl-terminal peptides | MITSUBISHI KASEI CORPORATION (JP) | 1989-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771659-B2 | Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway | SLC5A2, SLC5A1, MAT1A | CYP1A2 2032/4885CYP2C9 2491/4885ALDH1A1 1973/4885 |
| US-11911399-B2 | Treating and preventing disease with TMA and TMAO lowering agents | MAOB, DAO, ESD | CYP1A2 417/4885CYP2C9 349/4885ALDH1A1 239/4885 |
| US-20160089387-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | MAOB, DAO, ESD | CYP1A2 417/4885CYP2C9 349/4885ALDH1A1 239/4885 |
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | RNASE1, ENGASE, ENTPD5 | CYP1A2 2493/4885CYP2C9 3251/4885ALDH1A1 1021/4885 |
| US-20170266208-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | MAOB, DAO, ESD | CYP1A2 417/4885CYP2C9 349/4885ALDH1A1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.